Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Should Be Withdrawn For Safety Reasons, Public Citizen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Petition cites 22 cases of "serious" post-marketing events, including rhabdomyolysis, kidney problems and bleeding, in the U.S., U.K. and Canada.
Advertisement

Related Content

Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition
Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition
Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety
AstraZeneca Questions Reliability Of Crestor Adverse Event Reports
Crestor Rhabodomyolysis Cases At 10 Mg Dose Prompt Renewed Call For Drug’s Removal
Arava Will Stay On The Market: FDA Denies Public Citizen Petition For Withdrawal
AstraZeneca Crestor Promotions Tee Off With PGA
AstraZeneca Crestor Promotions Tee Off With PGA

Topics

Advertisement
UsernamePublicRestriction

Register

PS059020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel